Know Cancer

forgot password

Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer

Phase 2
20 Years
Open (Enrolling)
HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer

Thank you

Trial Information

Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer


I. To evaluate the changes in cancer stem cell (CSC) markers; % CD44 variant
(CD44v)-positive tumor cells and aldehyde dehydrogenase-1 (ALDH1) positivity before and
after study drug exposure and after concurrent preoperative chemotherapy.

II. To determine the pathological complete response (pCR) rate produced by lapatinib
(lapatinib ditosylate) + trastuzumab followed by concurrent preoperative lapatinib,
trastuzumab, and paclitaxel chemotherapy for operable human epidermal growth factor receptor
2-positive (HER2+) breast cancer.


I. To determine the cellular response rate produced by study drug exposure and/or concurrent
preoperative chemotherapy.

II. To determine cutoff values of baseline ratios of phosphorylated HER2 (pHER2)/HER2,
phosphorylated epidermal growth factor receptor (EGFR) (pEGFR)/EGFR, phosphorylated ERK
(pERK)/ERK and phosphorylated protein kinase B (pAkt)/Akt that are associated with pCR.

III. To assess the safety and tolerability of study therapy in Japanese women.


Drug exposure: Patients receive lapatinib ditosylate orally (PO) once daily (QD) and
trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease
progression or unacceptable toxicity.

Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30
minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the
absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy*
or mastectomy*.

After completion of study treatment, patients are followed up for 12 weeks.

NOTE: * Patients considered to be candidates for breast-conservation therapy (BCT) are
offered lumpectomy. Patients who are not considered to be candidates for BCT or who do not
desire BCT undergo total mastectomy.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed primary invasive breast

- Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or

- Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry
(IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+

- No distal metastasis (stage IV disease)

- No inflammatory breast cancer or bilateral breast cancer

- Must be Japanese

- Patients have Karnofsky ≥ 70%

- Leukocytes ≥ 3,000/mcL

- Absolute neutrophil count ≥ 1,500/mcL

- Hemoglobin ≥ 9.0 g/dL

- Platelets ≥ 75,000/mcL

- Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)

- Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvate transaminase[SGPT]) ≤
2.5 times institutional ULN

- Creatinine ≤ 1.5 times institutional ULN

- Patients must have left ventricular ejection fraction (LVEF) ≥ 50% by multi-gated
acquisition (MUGA) or echocardiography

- Patients must be able to take oral medications (i.e., no uncontrolled vomiting,
inability to swallow, or diagnosis of chronic malabsorption)

- Women of childbearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation as well as for at least 6 months after the last dose
of trastuzumab

- Ability to understand and willingness not only for treatment but also for undergoing
serial biopsies and sign a written informed consent document

- No patients with previous (within 10 years) or current history of malignant neoplasm
except for curatively treated basal and squamous cell carcinoma of the skin or
carcinoma in situ of the cervix

- No patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to lapatinib or other agents used in study

- No patients who have uncontrolled intercurrent illness including, but not limited to,
ongoing or active infection, symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements

- No pregnant women

- No patients who have family or personal history of congenital long or short QT
syndrome, Brugada syndrome, QT/QTc prolongation, or torsade de pointes

- No patients who have chronic gastrointestinal disease presenting with diarrhea
(inflammatory bowel disease, malabsorption, or ≥ grade 2 diarrhea of any etiology at

- No patients who have neuropathy ≥ grade 2 of any cause

- Patients have not received prior therapies for breast cancer

- No patients who have had chemotherapy or radiotherapy

- No patients who are receiving any other investigational agents

- No patients receiving any medications or substances that are inhibitors or inducers
of cytochrome P450 3A4 (CYP3A4)

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Expression of ALDH1 and CD44v change in quick score Q from baseline to 6 weeks and 18 weeks

Outcome Description:

For biomarkers ALDH1 and CD44v, the change in quick score Q from baseline to 6 weeks and 18 weeks time points will be calculated for each patient. For biomarker change pre- vs. post-treatment, a paired t-test will be used to examine whether the mean quick score has decreased significantly after the treatment. Descriptive statistics (mean, standard deviation, quartiles) will be summarized for the change in quick score post-treatment. We will also graphically present the mean ALDH1 and CD44 values at baseline, at 6 week, and at 18 week time points.

Outcome Time Frame:

From baseline to 18 weeks

Safety Issue:


Principal Investigator

Teruo Yamauchi

Investigator Role:

Principal Investigator

Investigator Affiliation:

Saint Luke's International Hospital


United States: Food and Drug Administration

Study ID:




Start Date:

July 2012

Completion Date:

Related Keywords:

  • HER2-positive Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Breast Neoplasms